Tranexamic acid (TXA) has an established history for being used to prevent bleeding in elective surgery, and is now recommended in a peer reviewed study to be used in the treatment of PPH (Post Partum Haemorrhage).
The research paper,"TRAnexamic Acid for Preventing Postpartum Hemorrhage after Vaginal Delivery," (TRAAP trial), reports on the 4000 women comparative trial of placebo and TXA. The TXA group demonstrated significant reduction in incidence of PPH in instrumental birth and episiotomy. It also demonstrates that there was no increase in severe adverse events in the TXA group at 3 months
In multicenter, randomized control study in France, researchers gave nearly 4,000 women in labor either one gram of TXA or a placebo. In the group that received the TXA, there was a reduction in the incidence of postpartum blood loss. In sub-group analysis, the researchers found that TXA reduced PPH in women with instrumental vaginal delivery and episiotomy. Further, there was no increase in severe adverse events in the TXA group, including thrombotic events, as compared to the placebo group in the three months after delivery.
Lead Author and chair, based at Bordeaux University Hospital, Loic Sentilles, MD, Ph.Dr, recommends that "TXA should be considered for women who deliver via operative vaginal delivery and episiotomy in conjunction with prophylactic oxytocin," The drug did identify a side effect of increased nausea and vomiting.
Petrina Duncan, Obstetrician, Gynaecologist, and mother. Writes about events, news issues and health issues.